Biotechnology, GlaxoSmithKline, Smallpox, Immunologic adjuvant, Vaccination, Vaccine
GSK sees lower profit this year, split plans on track
GSK sees lower profit this year, split plans on track https://t.co/lH9D4HBCkN https://t.co/MR8bMVZFv5
OpenBritain's GSK forecast a dip in earnings this year as it grapples with COVID-19 disruptions and invests in its pipeline of new drugs, and said its plans to split into two businesses were on track.
GSK sees lower profit this year, split plans on track https://t.co/lH9D4HBCkN https://t.co/MR8bMVZFv5
OpenGSK sees lower profit this year, split plans on track
Britain's GSK forecast a dip in earnings this year as it grapples with COVID-19 disruptions and invests in its pipeline of new drugs, and said its plans to split into two businesses were on ...
We are sorry, we could not find the related article
If you are curious about Biotech Essentials, the Influencers Review and Startups
Please click on:
Or signup to our newsletters
Other Essentials
AI Essentials
Robotics
Robotics
Ethics
Ethics
Research
Research
Applied Use Cases
Applied Use Cases
Marketing
Marketing
Healthcare
Healthcare
Cybersecurity
Cybersecurity
A Chinese biotech partners with GSK to boost its coronavirus vaccine development
A Chinese biotech has taken up vaccine maker GSK’s offer to share its vaccine-boosting platform as it works to develop a product that can stop infection from the novel coronavirus, the ...
2 of the world's biggest drugmakers just teamed up on a coronavirus vaccine, and they're aiming to launch it next year
A coronavirus vaccine is "core to the exit plan that the world needs" for this pandemic, GlaxoSmithKline CEO Emma Walmsley said.
U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal
The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, ...
GSK sets out plans to split following full year earnings miss
GSK has set out a two-year plan to split itself in two after missing its earnings targets in full year results and predicting a decline in earnings this year.
GSK Pledges One Billion Doses of Adjuvant Technology for COVID-19 Vaccine Candidates
The company is expanding its manufacturing efforts in Europe, Canada, the United Kingdom and the United States in order to meet this goal.
Using GSK and Dynavax tech, Clover kickstarts COVID vax trial, with data drop in August
After teaming up with GlaxoSmithKline and Dynavax early on in the pandemic, China biotech Clover Biopharmaceuticals has started trials of its COVID-19 vaccine and expects data in August.
Pfizer could haul in $3.5B in 2021 from COVID-19 vaccine: analyst
Pfizer is emerging as the clear frontrunner in the race to get a COVID-19 vaccine to market, but what will that be worth to investors? Analysts at SVB Leerink expect Pfizer and partner ...
Covid-19 roundup: J&J charts swift path to 1B vaccine doses; Embassy cable spotlights possible Wuhan lab connection to coronavirus
J&J, the first large pharmaceutical company to unveil its performance in the first quarter, acknowledged the coronavirus pandemic has had a sharp impact across its full-year guidance and ...
Sanofi, GSK team up on COVID-19 vaccine development
DUBLIN – Sanofi SA and Glaxosmithkline plc are lending their considerable weight to the urgent global effort to develop a vaccine for COVID-19 by teaming up to develop an adjuvanted ...
Dealmaking in a pandemic: partnerships that could expedite COVID-19 countermeasures
COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their ...
What are pharmaceutical companies doing to tackle COVID-19?
There are significant global efforts underway to diagnose, treat and prevent infections from the virus. Pharmaceutical companies are working globally to combat COVID-19.
Covid-19 is Big Pharma’s chance to impress. But who’ll do best?
AstraZeneca and GSK both release results this week. But picking winners in the sector may be complicated
Sanofi's latest investment signals long-term focus on vaccines
The new coronavirus has brought a renewed focus on the importance of vaccines. Now, Sanofi plans to spend hundreds of millions of dollars preparing for future pandemic risks.
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
Drugmaker GSK to split in two and create $12.7B spin-off consumer health company with Pfizer
The merger will lead to a market share of 7.3 percent, almost double that of its nearest rivals.
Despite pronouncements, no quick turnaround likely for COVID-19 treatments, vaccines
An inaccurate statement that President Trump made during a March 19 news briefing — that the malaria drug hydroxychloroquine had been approved as a COVID-19 treatment — demonstrates how ...
Coronavirus Drug Update: The Latest Info On Pharmaceutical Treatments And Vaccines
Forbes is tracking a definitive list of the pharmaceutical companies and startups working to find treatments and vaccines for the COVID-19 coronavirus.